Effect of irradiation on interleukin 6 and soluble interleukin 6 receptor modified melanoma genetic vaccine
Identifieur interne : 002892 ( Main/Exploration ); précédent : 002891; suivant : 002893Effect of irradiation on interleukin 6 and soluble interleukin 6 receptor modified melanoma genetic vaccine
Auteurs : J. Malicki ; M. Aciak ; G. Kosicka ; J. Kierzkowski ; M. Wiznerowicz ; A. MackiewiczSource :
- Reports of Practical Oncology [ 1428-2267 ] ; 1996.
English descriptors
- Teeft :
- Adherent cells, Allogeneic, Allogeneic melanoma cells, Allogeneic tumor cells, Assay, Autologous, Autologous cells, Autologous tumor cells, Celi, Cell basis, Cell number, Cell proliferation, Cellular vaccine, Cytokine, Cytokine secretion, Days postirradiation, Distant melanoma lesions, Dose dependant manner, Gene therapy, Greatpoland cancer center, Human melanoma, Immunize patients, Increases melanoma vaccine immunogenicity, Interleukin, Mackiewicz, Major reasons, Malicki, Melanoma, Melanoma cells, Melanoma cells proliferation, Melanoma gene therapy, Mrna, Mrna levels, Northern blot, Optimal dose, Postirradiation, Posttranscriptional level, Proliferation, Recombinant proteins, Retroviral vectors, Room temperature, Safe approach, Safety reasons, Secretion, Significant differences, Similar pattern, Similar results, Soluble interleukin, Specific mrna, Time point, Tissue culture plates, Transduced, Transduced cells, Tumor cells, Unirradiated cells, Vaccine, Vaccine preparation, Various doses, Viable cells.
Abstract
Abstract: We have designed phase I/II human melanoma gene therapy clinical protocol. The aim of the study was to actively immunize HLA-A1 and/or HLA-A2-positive patients with melanoma with an admixture of irradiated autologous tumor cells and allogeneic melanoma cells genetically engineered to secrete IL-6 and sIL-6R in order to elicit or enhance specific and nonspecific anti-melanoma immune responses to autologous tumor cells to eradicate distant melanoma lesions. Irradiation of autologous and allogeneic tumor cells is a key step in preparation of cellular vaccine because of two major reasons, (i) it inhibits cell proliferation which is crucial in the case of autologous cells which may form a tumor; (ii) it increases melanoma vaccine immunogenicity. The aim of the study was to estimate the optimal dose of ionizing radiation which will provide sterilization of both autologous and allogeneic melanoma cells and will ensure cytokine secretion.Human melanoma cells (Mich-1) were transduced with IL-6 and sIL-6R cDNA using double copy bicistronic retroviral vector. Parental and transduced cells were seeded at in six-well tissue culture plates and were irradiated with 10, 50, 100 and 200 Gy. Secretion of both recombinant proteins into culture was analyzed before and 24, 48, 72, 96 h and 6, 7, 10 and 12 days following irradiation. At the same time adherent cells were enumerated, evaluated for viability and proliferation. At 24, 48, 72 and 96 h postirradiation specific IL-6 and sIL-6R mRNA levels were analyzed.Irradiation of gene modified cells inhibited their proliferation in the dose dependant manner. Dose of 50 Gy sufficiently affected cell proliferation, however, for safety reasons we decided to use the dose of 100 Gy for vaccine preparation. Irradiation did not inhibit secretion of IL-6 and sIL-6R. In contrary, on a per cell basis it significantly increased their secretion which lasted 12 days postirradiation. Interestingly, we did not observe dose or time dependent differences in specific mRNA cellular levels suggesting that increased secretion of both proteins is regulated not on the transcriptional but rather on the posttranscriptional level. Taking all these facts into account we concluded that irradiation of tumor cells may provide an effective and safe approach for gene-modified vaccine preparation.
Url:
DOI: 10.1016/S1428-2267(96)70102-3
Affiliations:
Links toward previous steps (curation, corpus...)
- to stream Istex, to step Corpus: 001032
- to stream Istex, to step Curation: 001032
- to stream Istex, to step Checkpoint: 000689
- to stream Main, to step Merge: 002918
- to stream Main, to step Curation: 002892
Le document en format XML
<record><TEI wicri:istexFullTextTei="biblStruct"><teiHeader><fileDesc><titleStmt><title xml:lang="en">Effect of irradiation on interleukin 6 and soluble interleukin 6 receptor modified melanoma genetic vaccine</title><author><name sortKey="Malicki, J" sort="Malicki, J" uniqKey="Malicki J" first="J." last="Malicki">J. Malicki</name></author><author><name sortKey="Aciak, M" sort="Aciak, M" uniqKey="Aciak M" first="M." last="Aciak">M. Aciak</name></author><author><name sortKey="Kosicka, G" sort="Kosicka, G" uniqKey="Kosicka G" first="G." last="Kosicka">G. Kosicka</name></author><author><name sortKey="Kierzkowski, J" sort="Kierzkowski, J" uniqKey="Kierzkowski J" first="J." last="Kierzkowski">J. Kierzkowski</name></author><author><name sortKey="Wiznerowicz, M" sort="Wiznerowicz, M" uniqKey="Wiznerowicz M" first="M." last="Wiznerowicz">M. Wiznerowicz</name></author><author><name sortKey="Mackiewicz, A" sort="Mackiewicz, A" uniqKey="Mackiewicz A" first="A." last="Mackiewicz">A. Mackiewicz</name></author></titleStmt><publicationStmt><idno type="wicri:source">ISTEX</idno><idno type="RBID">ISTEX:284ABE9E7952FAFC5469C0AF6AD5BC42108ACA08</idno><date when="2009" year="2009">2009</date><idno type="doi">10.1016/S1428-2267(96)70102-3</idno><idno type="url">https://api.istex.fr/ark:/67375/6H6-FPL7K5JB-C/fulltext.pdf</idno><idno type="wicri:Area/Istex/Corpus">001032</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Corpus" wicri:corpus="ISTEX">001032</idno><idno type="wicri:Area/Istex/Curation">001032</idno><idno type="wicri:Area/Istex/Checkpoint">000689</idno><idno type="wicri:explorRef" wicri:stream="Istex" wicri:step="Checkpoint">000689</idno><idno type="wicri:doubleKey">1428-2267:2009:Malicki J:effect:of:irradiation</idno><idno type="wicri:Area/Main/Merge">002918</idno><idno type="wicri:Area/Main/Curation">002892</idno><idno type="wicri:Area/Main/Exploration">002892</idno></publicationStmt><sourceDesc><biblStruct><analytic><title level="a" type="main" xml:lang="en">Effect of irradiation on interleukin 6 and soluble interleukin 6 receptor modified melanoma genetic vaccine</title><author><name sortKey="Malicki, J" sort="Malicki, J" uniqKey="Malicki J" first="J." last="Malicki">J. Malicki</name><affiliation><wicri:noCountry code="subField">Pozna</wicri:noCountry></affiliation></author><author><name sortKey="Aciak, M" sort="Aciak, M" uniqKey="Aciak M" first="M." last="Aciak">M. Aciak</name><affiliation><wicri:noCountry code="no comma">Dept. of Cancer Immunology Chair of Oncology University School of Medical Sciences at GreatPoland Cancer Center</wicri:noCountry></affiliation></author><author><name sortKey="Kosicka, G" sort="Kosicka, G" uniqKey="Kosicka G" first="G." last="Kosicka">G. Kosicka</name><affiliation><wicri:noCountry code="subField">Pozna</wicri:noCountry></affiliation></author><author><name sortKey="Kierzkowski, J" sort="Kierzkowski, J" uniqKey="Kierzkowski J" first="J." last="Kierzkowski">J. Kierzkowski</name><affiliation><wicri:noCountry code="subField">Pozna</wicri:noCountry></affiliation></author><author><name sortKey="Wiznerowicz, M" sort="Wiznerowicz, M" uniqKey="Wiznerowicz M" first="M." last="Wiznerowicz">M. Wiznerowicz</name><affiliation><wicri:noCountry code="no comma">Dept. of Cancer Immunology Chair of Oncology University School of Medical Sciences at GreatPoland Cancer Center</wicri:noCountry></affiliation></author><author><name sortKey="Mackiewicz, A" sort="Mackiewicz, A" uniqKey="Mackiewicz A" first="A." last="Mackiewicz">A. Mackiewicz</name><affiliation><wicri:noCountry code="no comma">Dept. of Cancer Immunology Chair of Oncology University School of Medical Sciences at GreatPoland Cancer Center</wicri:noCountry></affiliation></author></analytic><monogr></monogr><series><title level="j">Reports of Practical Oncology</title><title level="j" type="abbrev">RPON</title><idno type="ISSN">1428-2267</idno><imprint><publisher>ELSEVIER</publisher><date type="published" when="1996">1996</date><biblScope unit="volume">1</biblScope><biblScope unit="issue">2</biblScope><biblScope unit="page" from="104">104</biblScope><biblScope unit="page" to="109">109</biblScope></imprint><idno type="ISSN">1428-2267</idno></series></biblStruct></sourceDesc><seriesStmt><idno type="ISSN">1428-2267</idno></seriesStmt></fileDesc><profileDesc><textClass><keywords scheme="Teeft" xml:lang="en"><term>Adherent cells</term><term>Allogeneic</term><term>Allogeneic melanoma cells</term><term>Allogeneic tumor cells</term><term>Assay</term><term>Autologous</term><term>Autologous cells</term><term>Autologous tumor cells</term><term>Celi</term><term>Cell basis</term><term>Cell number</term><term>Cell proliferation</term><term>Cellular vaccine</term><term>Cytokine</term><term>Cytokine secretion</term><term>Days postirradiation</term><term>Distant melanoma lesions</term><term>Dose dependant manner</term><term>Gene therapy</term><term>Greatpoland cancer center</term><term>Human melanoma</term><term>Immunize patients</term><term>Increases melanoma vaccine immunogenicity</term><term>Interleukin</term><term>Mackiewicz</term><term>Major reasons</term><term>Malicki</term><term>Melanoma</term><term>Melanoma cells</term><term>Melanoma cells proliferation</term><term>Melanoma gene therapy</term><term>Mrna</term><term>Mrna levels</term><term>Northern blot</term><term>Optimal dose</term><term>Postirradiation</term><term>Posttranscriptional level</term><term>Proliferation</term><term>Recombinant proteins</term><term>Retroviral vectors</term><term>Room temperature</term><term>Safe approach</term><term>Safety reasons</term><term>Secretion</term><term>Significant differences</term><term>Similar pattern</term><term>Similar results</term><term>Soluble interleukin</term><term>Specific mrna</term><term>Time point</term><term>Tissue culture plates</term><term>Transduced</term><term>Transduced cells</term><term>Tumor cells</term><term>Unirradiated cells</term><term>Vaccine</term><term>Vaccine preparation</term><term>Various doses</term><term>Viable cells</term></keywords></textClass><langUsage><language ident="en">en</language></langUsage></profileDesc></teiHeader><front><div type="abstract" xml:lang="en">Abstract: We have designed phase I/II human melanoma gene therapy clinical protocol. The aim of the study was to actively immunize HLA-A1 and/or HLA-A2-positive patients with melanoma with an admixture of irradiated autologous tumor cells and allogeneic melanoma cells genetically engineered to secrete IL-6 and sIL-6R in order to elicit or enhance specific and nonspecific anti-melanoma immune responses to autologous tumor cells to eradicate distant melanoma lesions. Irradiation of autologous and allogeneic tumor cells is a key step in preparation of cellular vaccine because of two major reasons, (i) it inhibits cell proliferation which is crucial in the case of autologous cells which may form a tumor; (ii) it increases melanoma vaccine immunogenicity. The aim of the study was to estimate the optimal dose of ionizing radiation which will provide sterilization of both autologous and allogeneic melanoma cells and will ensure cytokine secretion.Human melanoma cells (Mich-1) were transduced with IL-6 and sIL-6R cDNA using double copy bicistronic retroviral vector. Parental and transduced cells were seeded at in six-well tissue culture plates and were irradiated with 10, 50, 100 and 200 Gy. Secretion of both recombinant proteins into culture was analyzed before and 24, 48, 72, 96 h and 6, 7, 10 and 12 days following irradiation. At the same time adherent cells were enumerated, evaluated for viability and proliferation. At 24, 48, 72 and 96 h postirradiation specific IL-6 and sIL-6R mRNA levels were analyzed.Irradiation of gene modified cells inhibited their proliferation in the dose dependant manner. Dose of 50 Gy sufficiently affected cell proliferation, however, for safety reasons we decided to use the dose of 100 Gy for vaccine preparation. Irradiation did not inhibit secretion of IL-6 and sIL-6R. In contrary, on a per cell basis it significantly increased their secretion which lasted 12 days postirradiation. Interestingly, we did not observe dose or time dependent differences in specific mRNA cellular levels suggesting that increased secretion of both proteins is regulated not on the transcriptional but rather on the posttranscriptional level. Taking all these facts into account we concluded that irradiation of tumor cells may provide an effective and safe approach for gene-modified vaccine preparation.</div></front></TEI><affiliations><list></list><tree><noCountry><name sortKey="Aciak, M" sort="Aciak, M" uniqKey="Aciak M" first="M." last="Aciak">M. Aciak</name><name sortKey="Kierzkowski, J" sort="Kierzkowski, J" uniqKey="Kierzkowski J" first="J." last="Kierzkowski">J. Kierzkowski</name><name sortKey="Kosicka, G" sort="Kosicka, G" uniqKey="Kosicka G" first="G." last="Kosicka">G. Kosicka</name><name sortKey="Mackiewicz, A" sort="Mackiewicz, A" uniqKey="Mackiewicz A" first="A." last="Mackiewicz">A. Mackiewicz</name><name sortKey="Malicki, J" sort="Malicki, J" uniqKey="Malicki J" first="J." last="Malicki">J. Malicki</name><name sortKey="Wiznerowicz, M" sort="Wiznerowicz, M" uniqKey="Wiznerowicz M" first="M." last="Wiznerowicz">M. Wiznerowicz</name></noCountry></tree></affiliations></record>Pour manipuler ce document sous Unix (Dilib)
EXPLOR_STEP=$WICRI_ROOT/Sante/explor/MersV1/Data/Main/Exploration
HfdSelect -h $EXPLOR_STEP/biblio.hfd -nk 002892 | SxmlIndent | more
Ou
HfdSelect -h $EXPLOR_AREA/Data/Main/Exploration/biblio.hfd -nk 002892 | SxmlIndent | more
Pour mettre un lien sur cette page dans le réseau Wicri
{{Explor lien
|wiki= Sante
|area= MersV1
|flux= Main
|étape= Exploration
|type= RBID
|clé= ISTEX:284ABE9E7952FAFC5469C0AF6AD5BC42108ACA08
|texte= Effect of irradiation on interleukin 6 and soluble interleukin 6 receptor modified melanoma genetic vaccine
}}
| This area was generated with Dilib version V0.6.33. |  |